Bedrijfsoverzicht
Daxor Corporation is a specialized entity within the healthcare sector, specifically focusing on the medical instruments and supplies industry, where it develops and markets advanced diagnostic solutions for blood volume analysis. The company's primary operational focus involves the creation of the BVA-100 Blood Volume Analyzer, an instrument designed to measure human blood volume, which functions in conjunction with Volumex, a single-use radiopharmaceutical diagnostic injection and collection kit. As a small-cap organization, Daxor Corporation currently holds a market capitalization of $55.15M and generates annual revenue (TTM) of $26,688, with no specific employee count data available in the provided records. These valuation and revenue figures indicate that the company operates as a niche player with a relatively modest scale compared to large-cap medical device manufacturers, suggesting a business model that relies on specialized product offerings rather than broad market volume. The market capitalization reflects investor sentiment regarding the company's current operational capabilities and future potential within the medical instrumentation landscape, while the revenue figure highlights the current scale of its commercial operations.
Financiële gezondheid
The company reported revenue of $26,688 over the trailing twelve months, accompanied by a net income of $9.17M and an EBITDA figure that is not available for disclosure. The significant discrepancy between the reported revenue of $26,688 and the net income of $9.17M reveals a highly unusual cost structure where reported costs appear to be negligible relative to the income statement, or where revenue and income figures are presented on different scales not immediately reconcilable by standard gross margin calculations. Despite this revenue figure, the company generated free cash flow of $100,248, which indicates a positive cash generation capability and suggests a degree of financial flexibility that could support operational continuity or strategic initiatives. The margin profile presents a complex picture: the gross margin stands at 100.0%, implying that the cost of goods sold is effectively zero or fully covered by revenue in the reported period, while the operating margin is listed at -9660.6% and the profit margin at 34359.2%, figures that deviate significantly from standard financial reporting norms and suggest specific accounting treatments or data anomalies. On the balance sheet, the company reports a cash position marked as N/A and total debt at $0, resulting in a debt-to-equity ratio that is not applicable due to the absence of debt figures. The current ratio is recorded at 0.08, which indicates a potential liquidity challenge where current assets are significantly lower than current liabilities, suggesting a tight short-term liquidity position. Return on Equity is calculated at 22.5%, demonstrating high efficiency in generating returns for shareholders, whereas Return on Assets stands at -1.6%, indicating that the asset base is not generating positive returns on a book value basis in the traditional sense.
Waarderingsbeoordeling
The trailing twelve-month P/E ratio is 5.77, while the forward P/E ratio is not available, implying that the market is currently pricing in earnings without a clear projected earnings trajectory or that forward estimates are unavailable. The price-to-book ratio is 1.04, suggesting that the company's market valuation is nearly equivalent to its book value, indicating a lack of significant market premium or discount relative to its net asset value. Alternative valuation metrics include a price-to-sales ratio of 2066.65 and an EV/EBITDA ratio that is not available, figures that suggest the stock price is heavily weighted against sales revenue and that earnings-based multiples are difficult to apply due to the unusual financial data presented. The stock has traded within a 52-week range defined by a high of $14.76 and a low of $7.10, meaning the current price sits at a specific point within this band, though the exact percentage deviation requires the current share price which is not explicitly defined in the provided text beyond these bounds. The beta value is 0.14, indicating that the stock's price volatility is significantly lower than that of the broader market, suggesting it behaves as a low-volatility asset relative to the general equity market movements.
Growth & Income
Revenue growth year-over-year is recorded at -82.6%, while earnings growth year-over-year is 329.3%, indicating that earnings are growing at a rate vastly faster than revenue, a dynamic often seen in companies with unique accounting situations or non-recurring income components. The company does not pay dividends, as evidenced by a dividend yield of N/A and a payout ratio of 0.0%, meaning that all available earnings are theoretically available for reinvestment rather than distribution to shareholders. Since the company is not a dividend payer, it does not distribute cash to shareholders, and the earnings growth rate of 329.3% must be viewed in the context of the declining revenue to understand the source of such high earnings expansion. The overall growth and income profile is characterized by a contraction in top-line revenue alongside a massive expansion in reported net income, creating a divergent growth trajectory that investors must analyze carefully alongside the unusual margin and liquidity metrics.